Frontiers • visionary makeover

Aria Aug 06, 2026

Overview of Frontiers

Frontiers
Frontiers

Open access publisher of peer-reviewed scientific articles across the entire spectrum of academia. Research network for academics to stay up-to-date with the latest scientific publications, events, blogs and news.

PDF Effectiveness and safety of GLP 1 receptor agonists versus SGLT 2
PDF Effectiveness and safety of GLP 1 receptor agonists versus SGLT 2

Frontiers There are too many open problems to list. Some are too broad to pursue, and others are too small to matter much. A few combine three qualities: they are important, tractable, and close to the edge of what we understand or can do. We call these frontiers . This site is an attempt to collect them. Is something missing? Email me →

Key Details About Frontiers

PDF GLP 1 receptor agonists and cardiorenal outcomes in type 2
PDF GLP 1 receptor agonists and cardiorenal outcomes in type 2

Frontiers in Allergy Frontiers in Allergy is one of the most cited journals in its field, advancing our understanding of allergic diseases and how to manage them.

At Frontiers USA, our mission is to inspire transformational movements to Christ within unengaged Muslim people groups by sending teams to catalyze change, because even the most uncharted frontiers need Jesus.

Anti Inflammatory Effects of GLP 1 Receptor Activation in the Brain
Anti Inflammatory Effects of GLP 1 Receptor Activation in the Brain

Frontiers Media

Frontiers Media is a Swiss-based publisher of peer-reviewed, open access journals in various fields of science, technology, and medicine. It was founded in 2007 by Kamila and Henry Markram and has over 230 journals, some of which are considered megajournals.

With love and respect, inviting all Muslim peoples to follow Jesus Select a National office

GLP 1 Agonists in Type 2 Diabetes Care PDF
GLP 1 Agonists in Type 2 Diabetes Care PDF

Overview of Frontiers

Benchmarking software engineering skill at the edge of human ability

FRONTIERS is the science journalism initiative funded by the European Research Council to design a residency program for journalists wishing to experience an immersive period in a research institution. The FRONTIERS project is set to run from 2023 to 2027. During this time, the FRONTIERS Team plans to enable up to 40 science journalists to spend time with research teams, working on their own ...

SGLT2 Inhibitors vs GLP 1 Agonists to Treat the Heart the Kidneys
SGLT2 Inhibitors vs GLP 1 Agonists to Treat the Heart the Kidneys
GLP 1 Receptor Agonists for the Reduction of Atherosclerotic
GLP 1 Receptor Agonists for the Reduction of Atherosclerotic
Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes
Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes
See How GLP 1 Works Through Graphics Pictures And Charts
See How GLP 1 Works Through Graphics Pictures And Charts
Glucagon like Peptide 1 Receptor Agonists in Patients with Type 2
Glucagon like Peptide 1 Receptor Agonists in Patients with Type 2
Glucagon like Peptide 1 Receptor Agonists GLP 1 RAs A Pan Steatotic
Glucagon like Peptide 1 Receptor Agonists GLP 1 RAs A Pan Steatotic
New Developments in Pharmacological Treatment of Obesity and Type 2
New Developments in Pharmacological Treatment of Obesity and Type 2